Form 4: Entera Bio Director Receives Equity Compensation

Entera Bio Ltd. director Gerald M. Lieberman received 38,294 ordinary shares in lieu of cash fees and an annual grant of 33,505 stock options.

Summary

• Director Gerald M. Lieberman acquired 38,294 ordinary shares of Entera Bio Ltd. on January 1, 2026.
• These shares were awarded in lieu of cash fees for his services as a director for the 2025 fiscal year.
• He also acquired 33,505 stock options with an exercise price of $1.94, which represent the annual grant to directors.
• The stock options vest ratably on a quarterly basis over a one-year period starting January 1, 2026, and expire on January 1, 2036.
• Following these transactions, Mr. Lieberman directly beneficially owns 338,454 ordinary shares and 33,505 stock options.
• An additional 6,200 ordinary shares are indirectly owned by a Trust for which the reporting person disclaims beneficial ownership, except for any pecuniary interest.

Sentiment

Score: 7

Explanation: The filing indicates routine director compensation through equity, which is generally positive for aligning interests. No negative or significantly surprising information is present.

Positives

• Director Gerald M. Lieberman received 38,294 ordinary shares as compensation, aligning his interests with shareholders.
• The annual grant of 33,505 stock options further incentivizes the director's long-term commitment to the company's performance.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports ownership changes.

Future Outlook

The vesting schedule for the stock options, commencing January 1, 2026, over a one-year period, indicates a forward-looking incentive structure for the director.

Industry Context

This filing reflects standard corporate governance practices where directors receive equity compensation, aligning their interests with long-term shareholder value. Such compensation structures are common in the biotechnology and pharmaceutical sectors, where long-term value creation is paramount.

Comparison to Industry Standards

• The practice of compensating directors with equity, including shares in lieu of cash fees and stock options, is a widely accepted standard in publicly traded companies, particularly within the biotech industry.
• This aligns director incentives with shareholder interests, a common benchmark for good corporate governance.
• Specific comparable companies or projects are not detailed in this filing, but similar compensation structures are observed across peers like BioNTech, Moderna, or smaller biotech firms, where equity grants are a key component of executive and director remuneration.

Corporate Governance

Related Party Transactions

• The indirect ownership of 6,200 shares by a Trust for which the Reporting Person's grandchild is the beneficiary and spouse is the Trustee could be considered a related party arrangement, though beneficial ownership is disclaimed except for pecuniary interest.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's interests with shareholders, potentially fostering long-term value creation.
• Management: The compensation structure provides incentives for the director to contribute to the company's success.

Next Steps

• The stock options will vest ratably on a quarterly basis over a one-year period starting January 1, 2026.

Key Dates

Recommendation

This Form 4 filing details routine director compensation through equity grants, which is a standard practice to align director and shareholder interests. It does not contain information that would fundamentally alter the investment thesis for Entera Bio Ltd., hence a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Entera Bio, ENTX, Form 4, Beneficial Ownership, Director Compensation, Stock Options, Equity Grant, Insider Transaction, Gerald M. Lieberman